Loading [MathJax]/jax/output/SVG/jax.js
Review

Biophysical insights into nanomaterial-induced DNA damage: mechanisms, challenges, and future directions

  • Received: 19 July 2024 Revised: 23 August 2024 Accepted: 06 September 2024 Published: 11 September 2024
  • Nanomaterials have garnered significant attention due to their unique properties and wide-ranging applications in medicine and biophysics. However, their interactions with biological systems, particularly DNA, raise critical concerns about genotoxicity and potential long-term health risks. This review delves into the biophysical mechanisms underlying nanomaterial-induced DNA damage, highlighting recent insights, current challenges, and future research directions. We explore how the physicochemical properties of nanomaterials influence their interaction with DNA, the pathways through which they induce damage, and the biophysical methods employed to study these processes.

    Citation: James C.L. Chow. Biophysical insights into nanomaterial-induced DNA damage: mechanisms, challenges, and future directions[J]. AIMS Biophysics, 2024, 11(3): 340-369. doi: 10.3934/biophy.2024019

    Related Papers:

    [1] Hengjie Peng, Changcheng Xiang . A Filippov tumor-immune system with antigenicity. AIMS Mathematics, 2023, 8(8): 19699-19718. doi: 10.3934/math.20231004
    [2] Shifan Luo, Dongshu Wang, Wenxiu Li . Dynamic analysis of a SIV Filippov system with media coverage and protective measures. AIMS Mathematics, 2022, 7(7): 13469-13492. doi: 10.3934/math.2022745
    [3] Saima Rashid, Fahd Jarad, Sobhy A. A. El-Marouf, Sayed K. Elagan . Global dynamics of deterministic-stochastic dengue infection model including multi specific receptors via crossover effects. AIMS Mathematics, 2023, 8(3): 6466-6503. doi: 10.3934/math.2023327
    [4] Liang Hong, Jie Li, Libin Rong, Xia Wang . Global dynamics of a delayed model with cytokine-enhanced viral infection and cell-to-cell transmission. AIMS Mathematics, 2024, 9(6): 16280-16296. doi: 10.3934/math.2024788
    [5] Noufe H. Aljahdaly, Nouf A. Almushaity . A diffusive cancer model with virotherapy: Studying the immune response and its analytical simulation. AIMS Mathematics, 2023, 8(5): 10905-10928. doi: 10.3934/math.2023553
    [6] Ru Meng, Yantao Luo, Tingting Zheng . Stability analysis for a HIV model with cell-to-cell transmission, two immune responses and induced apoptosis. AIMS Mathematics, 2024, 9(6): 14786-14806. doi: 10.3934/math.2024719
    [7] Ahmed M. Elaiw, Ghadeer S. Alsaadi, Aatef D. Hobiny . Global co-dynamics of viral infections with saturated incidence. AIMS Mathematics, 2024, 9(6): 13770-13818. doi: 10.3934/math.2024671
    [8] Irina Volinsky, Svetlana Bunimovich-Mendrazitsky . Mathematical analysis of tumor-free equilibrium in BCG treatment with effective IL-2 infusion for bladder cancer model. AIMS Mathematics, 2022, 7(9): 16388-16406. doi: 10.3934/math.2022896
    [9] S. M. E. K. Chowdhury, J. T. Chowdhury, Shams Forruque Ahmed, Praveen Agarwal, Irfan Anjum Badruddin, Sarfaraz Kamangar . Mathematical modelling of COVID-19 disease dynamics: Interaction between immune system and SARS-CoV-2 within host. AIMS Mathematics, 2022, 7(2): 2618-2633. doi: 10.3934/math.2022147
    [10] Qiongru Wu, Ling Yu, Xuezhi Li, Wei Li . Dynamic analysis of a Filippov blood glucose insulin model. AIMS Mathematics, 2024, 9(7): 18356-18373. doi: 10.3934/math.2024895
  • Nanomaterials have garnered significant attention due to their unique properties and wide-ranging applications in medicine and biophysics. However, their interactions with biological systems, particularly DNA, raise critical concerns about genotoxicity and potential long-term health risks. This review delves into the biophysical mechanisms underlying nanomaterial-induced DNA damage, highlighting recent insights, current challenges, and future research directions. We explore how the physicochemical properties of nanomaterials influence their interaction with DNA, the pathways through which they induce damage, and the biophysical methods employed to study these processes.



    Epidemics have posed a significant threat to global public health over the years. The emergence of COVID-19 in 2019 has had a profound impact on human health, the global economy, and social behavior. Nevertheless, the effective addressing of disease transmission remains a challenge. Mathematical modeling has emerged as a crucial tool in tackling this challenge. Numerous disease models have been developed in existing literature to study and control the spread of epidemics. It is important to note that mathematical models based on ordinary differential equations (i.e., classical derivatives) have their limitations and may not accurately capture biological phenomena. On the other hand, fractional models can offer a relatively more accurate understanding of disease outbreaks. Therefore, they are increasingly being used to simulate disease transmission with higher accuracy. Relevant literature on fractional models can be found in [1,2,3,4,5]. In addition, as another epidemic that endangers human health, the acute viral infection caused by the human immunodeficiency virus (HIV) studied in this paper is also a hot issue in society. Many researchers aim to capture the dynamics between viral and antiviral immune responses through mathematical modeling.

    As we all know, HIV, which causes AIDS, can directly infect the immune system (mainly regulating CD4+ T cells). The consequences of this impact are a continuous decrease in the number of CD4+ T cells, ultimately leading to the death of infected individuals due to immune system collapse. The highly active antiretroviral therapy (HAART) currently in widespread use has been shown to improve the survival probability of HIV patients and reduce the incidence rate [6,7]. This therapy effectively suppresses the plasma virus to levels below the standard detection for extended periods and even halts viral evolution [8,9]. However, many complex problems arise after long-term use, such as obvious drug resistance, and, due to the side effects of antiviral drugs, some AIDS patients have poor compliance with antiviral therapy [10,11,12].

    In fact, numerous mathematical models have been put forth to describe the dynamics of HIV and elucidate various phenomena. The effect of antiviral therapy has been investigated by some researchers [13,14,15,16]. In their work, Xiao et al.[13] analyzed the free terminal time optimal tracking control problem to determine the optimal multidrug therapy for HIV, considering both the optimal time frame and therapeutic strategies. The literature [17,18,19,20,21,22,23,24] incorporated the expansion delay of immune cells to discuss the local and global stability of equilibrium solutions. In particular, [17] indicates that such an unstable equilibrium will exhibit oscillatory solutions of increasing amplitude. In recent years, realizing gradually the multiple effects of spatial heterogeneity and mobility, many scholars utilized the reaction-diffusion equation to investigate the spatial effect of viral infection [23,24,25].

    Several recent clinical studies have exhibited that structured treatment interruptions (STIs) can be used for early treatment of HIV infection to achieve sustained specific immunity. For some chronically infected individuals who may require lifelong medication, this may be a beneficial option as it can help patients rebuild their immune system during periods of non-medication[26]. While numerous mathematical models have been employed for simulating continuous therapy [27,28,29], there is scant investigation on modeling structured interruptions in treatment.

    To investigate strategies for STIs, Tang et al.[30] suggested a piecewise model for delineating CD4 cell-guided STIs. The system provides an explanation for some controversial clinical research results. In 2017, Tang et al.[31] proposed a mathematical model to describe the dynamics of the interplay between the virus and the immune system. This model takes into consideration the structured treatment guided by effector cells while also incorporating the use of combined antiretroviral therapy and interleukin (IL)-2 treatment. However, they posit a linear growth pattern for the HIV virus [31], which does not accurately reflect the true dynamics of the virus. Some clinical facts show that the growth of HIV may have a saturation effect[32].

    To better illustrate the non-linear evolutionary characteristics of the interplay between virus and immune response, the immunosuppressive infection model was devised by Komarova et al.[33]. The model is given as follows:

    {dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz, (1.1)

    The assumptions in model (1.1) are as follows:

    y and z represent the population sizes of the virus and immune cells, respectively. The virus population is assumed to grow logistically: The replication rate at low viral loads, denoted as r, is expected to decrease linearly with an increase in the viral load until it becomes zero at a viral load K.

    c represents the immune intensity, while the proliferation term is denoted as cyz/(1+hy). Thus, the assessment of immune cell proliferation depends on both the immune cells and the virus. The inhibitory effect of the virus on the proliferation of immune cells is represented by the variable η.

    ❑ The viral elimination rate, denoted as a, is a result of natural decay and antiretroviral therapy. Immune cells, which have the ability to kill the virus at a rate pyz, also have a death rate b. Furthermore, these immune cells can be inhibited by the virus at a rate qyz.

    The study conducted in [33] aimed to investigate the optimal timing and duration of antiviral treatment. The research elucidates the presence of bistability dynamics, wherein a stable state without immunity coexists alongside a stable state with immunity. Meanwhile, this model demonstrates the attainment of sustained immunity following the interruption of therapy. Additionally, Wang et al.[34] expanded on this model and uncovered that bistability arises within the range delineated by the post-treatment control threshold and the elite control threshold.

    Following the pioneer works above[30,31,32,33,34], in this thesis, we extend model (1.1) by proposing a Filippov immunosuppressive infection model with viral logistic growth and effector cell-guided therapy. We have proposed the following model:

    {dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz,}z>ET,dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz+εz,}z<ET. (1.2)

    We assume that the sole course of action is to administer antiretroviral therapy to the patient if the number of effector cells exceeds the critical value ET. Conversely, when the count falls below the ET threshold, a combination of antiretroviral therapy and immune therapy is concurrently implemented. In this context, ε represents the rate at which effector cells grow as a result of immune therapy, like the treatment of interleukin (IL)-2. As the interpretation of other parameters is consistent with a model (1.1), all parameters in (1.2) remain nonnegative.

    This paper presents a switching model with viral load logistic growth to analyze effector cell-guided treatment and assess the threshold strategy's effectiveness. The following section provides an overview of the model, defining the switching system, and summarizing the dynamic behavior of the subsystems. Additionally, in Section 3, there is a discussion on sliding mode and dynamics, exploring the presence of a sliding domain and pseudo-equilibrium. The global dynamics of the proposed model are examined in Section 4, while Section 5 focuses on the boundary equilibrium bifurcation of the system. Finally, the paper concludes with discussions and biological implications.

    By rearranging the system (1.2), we can obtain a generic planar system in the form of Filippov given by

    {dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz+ϕεz, (2.1)

    with

    {ϕ=0,ifH(X)=zET>0,ϕ=1,ifH(X)=zET<0. (2.2)

    Systems (2.1) and (2.2) describe a Filippov immunosuppressive infection model where (2.1) is considered a free system when ϕ=0(i.e.,z>ET), indicating that the patient receives antiretroviral therapy. On the other hand, (2.1) as a control system when ϕ=1(i.e.,z<ET) reflects the simultaneous utilization of antiretroviral therapy and immune therapy.

    Let R2+={X=(y,z)T|y0,z0}, S1={XR2+|H(X)>0}, and S2={XR2+|H(X)<0} with H(X) being a smooth scale function. For convenience, we further denote

    FS1(X)=(ry(1yK)aypyz,cyz1+ηybzqyz)T,FS2(X)=(ry(1yK)aypyz,cyz1+ηybzqyz+εz)T. (2.3)

    We can rewrite model (1.2) to represent the Filippov system as follows:

    ˙X={FS1(X), XS1,FS2(X), XS2. (2.4)

    The discontinuous boundary Σ that separates the two areas can be represented as:

    Σ={XR2+|H(X)=0}. (2.5)

    It is evident that R2+=S1ΣS2. Henceforth, we shall designate the Filippov system (2.4) as subsystem S1 when it is defined within region S1, and as subsystem S2 when defined within region S2.

    Let

    σ(X)=HX(X),FS1(X)HX(X),FS2(X)=FS1H(X)FS2H(X), (2.6)

    where , represents the standard scalar product and HX(X) denotes the gradient of H(X) that remains nonvanishing on Σ. FSiH(X)=FSigradH(X) is the Lie derivative of H with respect to the vector field FSi (i=1,2) at X. To analyze the direction of the vector field [FS1(X),FS2(X)], through a specific point XΣ, we categorize the areas on Σ based on whether the vector field points towards it:

    (a) Crossing region:

    Σc={XΣ|FS1H(X)FS2H(X)>0}, (2.7)

    (b) Sliding region:

    Σs={XΣ|FS1H(X)<0,FS2H(X)>0}, (2.8)

    (c) Escaping region:

    Σe={XΣ|FS1H(X)>0,FS2H(X)<0}. (2.9)

    Throughout the paper, it is crucial to have a clear understanding of the definitions regarding all types of equilibria in Filippov systems [35,36].

    Definition 2.1. If FS1(X)=0,H(X)>0, or FS2(X)=0, H(X)<0, then X is defined as a real equilibrium of the Filippov system (2.4). Analogously, if FS1(X)=0, H(X)<0, or FS2(X)=0,H(X)>0, then X is a virtual equilibrium. Both the real and virtual equilibriums are named as regular equilibria.

    Definition 2.2. If X is an equilibrium of the sliding mode of system (2.4), and satisfies (1λ)FS1(X)+λFS2(X)=0,H(X)=0 with 0<λ<1, then X is a pseudo-equilibrium, where

    λ=HX(X),FS1(X)HX(X),FS1(X)FS2(X). (2.10)

    Definition 2.3. If FS1(X)=0,H(X)=0, or FS2(X)=0,H(X)=0, then X is defined a boundary equilibrium of Filippov system (2.4).

    Definition 2.4. If FS1H(X)=0 but F2S1H(X)>0(F2S1H(X)<0), then X is a visible (invisible) Σ-fold point of FS1. The same definition applies to FS2.

    Definition 2.5. If XΣs and FS1H(X)=0 or FS2H(X)=0, then X is defined a tangent point of Filippov system (2.4).

    The model equation for the free system S1 is as follows:

    {dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz. (2.11)

    We can easily define a threshold R0=ra. If R0<1, subsystem S1 has only one uninfected equilibrium E10=(0,0); if R0>1, then subsystem S1 also has an immune-free equilibrium E11=(y1,0)=(K(1ar),0).

    We certainly get an equation for y

    S1(y)=qηy2(cqbη)y+b=0, (2.12)

    It can be confirmed that S1(y)=0 has a sole solution when c=q+bη±2bqη. Denote c1=q+bη2bqη and c2=q+bη+2bqη. Thus, we have two possible positive roots

    y11=BB24bqη2qη,y12=B+B24bqη2qη, (2.13)

    when c>c2, where B=cqbη. Substituting y11 or y12 into the first equation of (2.11), we get

    z1i=r(1y1iK)ap=a[ra(1y1iK)1]p(i=1,2). (2.14)

    Let R1i=ra(1y1iK)(i=1,2). Hence, the subsystem S1 has two immune equilibriums E11=(y11,z11) and E12=(y12,z12) when R1i>1 and c>c2 are satisfied.

    In fact, subsystem S1 has been extensively examined in a previous study. Therefore, we will provide an overview of the main findings without delving into specific calculations. For more details on the discussion of the stability analysis of this system, please consult [34]. Here, we define three thresholds by referring [34], i.e., c=q+bη+2qηK(1ar), c=q+bη+bK(1ar)+qηK(1ar), and threshold Rc1=1+rbqηaqηK. Moreover, we have the following

    Lemma 2.1. If R0<1, the infection-free equilibrium E10 is globally asymptotically stable (GAS). If R0>1, we have E11 as locally asymptotically stable (LAS) when 0<c<c2 or c2<c<c, and E11 is unstable when c>c. The immune equilibrium E11 is LAS when Rc1>R0>1 and c>c or R0>Rc1 and c2<c. Suppose R0>Rc1>1 and c2<c<c, then positive equilibrium E11 is LAS and E12 is a unstable saddle.

    Remark 2.1. For R0>Rc1>1 and c2<c<c, subsystem S1 has bistable behavior, i.e., E11 and E11 are bistable but the equilibrium E12 is an unstable saddle. In other cases, subsystem S1 does not exhibit bistable behavior. Note that the post-treatment control threshold is represented by c2, while the elite control threshold is denoted as c. The range between c2 and c is referred to as the bistable interval.

    Dynamical analysis of the subsystem S1 is presented in Table 1.

    Table 1.  Dynamical analysis of the subsystem S1.
    Condition E10 E11 E11 E12 subsystem S1
    R0<1 GAS Asymptotically tends to E10
    R0>1, 0<c<c2 US LAS Asymptotically tends to E11
    R0>Rc1>1, c2<c<c US LAS LAS US Bistable
    R0>Rc1>1, c<c<c US US LAS US Asymptotically tends to E11
    R0>Rc1>1, c<c US US LAS Asymptotically tends to E11
    Rc1>R0>1, 0<c<c US LAS Asymptotically tends to E11
    Rc1>R0>1, c<c US US LAS Asymptotically tends to E11

     | Show Table
    DownLoad: CSV

    Control system S2 gives

    {dydt=ry(1yK)aypyz,dzdt=cyz1+ηybzqyz+εz. (2.15)

    The basic reproduction number is also R0=ra for subsystem S2. Similarly, we can get uninfected equilibrium E20=(0,0) and the immune-free equilibrium E21=(K(1ar),0). Thus, we use E10=E20=E0 and E21=E11=E1 in the following.

    Using the same method as subsystem S1, we can derive the following quadratic equation for y

    S2(y)=qηy2(cqbη+εη)y+bε=0. (2.16)

    Let c3=q+(bε)η2qη(bε) and c4=q+(bε)η+2qη(bε), then there are two possible positive roots

    y2i=DD24qη(bε)2qη(i=1,2), (2.17)

    when c>c4, where D=cqbη+εη. It follows that

    z21=a[ra(1y21K)1]p,z22=a[ra(1y22K)1]p. (2.18)

    In fact, we can obtain y21<y11<y12<y22 by doing a simple calculation. Now, we define R2i=ra(1y2iK)(i=1,2). For subsystem S2, we have two positive equilibriums E21=(y21,z21) and E22=(y22,z22) when c>c4, b>ε and R2i>1(i=1,2) hold. Furthermore, following a similar approach to subsystem S1, we can also define thresholds c=q+(bε)η+2qηK(1ar), c=q+(bε)η+bεK(1ar)+qηK(1ar), and Rc2=1+rqη(bε)aqηK. Meanwhile, we have the following results about the behaviors of subsystem S2 by using the consistent method with S1.

    Lemma 2.2. Suppose R0<1, the equilibrium E20 is GAS. Suppose R0>1, then E21 is LAS when 0<c<c4 or c4<c<c, and E21 is unstable when c>c. If Rc2>R0>1 and c>c or R0>Rc2 and c4<c, the subsystem S2 has a locally asymptotically stable immune equilibrium E21; if R0>Rc2>1 and c4<c<c, then positive equilibrium E21 is LAS and E22 is an unstable saddle.

    Dynamical analysis of the subsystem S2 is shown in Table 2.

    Table 2.  Dynamical analysis of the subsystem S2.
    Condition E20 E21 E21 E22 subsystem S2
    R0<1 GAS Asymptotically tends to E20
    R0>1, 0<c<c4 US LAS Asymptotically tends to E21
    R0>Rc2>1, c4<c<c US LAS LAS US Bistable
    R0>Rc2>1, c<c<c US US LAS US Asymptotically tends to E21
    R0>Rc2>1, c<c US US LAS Asymptotically tends to E21
    Rc2>R0>1, 0<c<c US LAS Asymptotically tends to E21
    Rc2>R0>1, c<c US US LAS Asymptotically tends to E21

     | Show Table
    DownLoad: CSV

    In this section, we will provide a brief overview of the definitions pertaining to the sliding segment and crossing segment discussed in Section 2. We have σ(X)=HX(X),FS1(X)HX(X),FS2(X). Here, HX(X)=(Hy,Hz) is the non-vanishing gradient on the discontinuity boundary Σ, where H=zET. Therefore, we denote

    σ(X)=(cyz1+ηybzqyz)(cyz1+ηybzqyz+εz), (3.1)

    and calculating the inequality σ(X)<0 obtains y21<y<y11 and y12<y<y22. Naturally, we can verify that there are FS1,HX(X)=cyz1+ηybzqyz<0 and FS2,HX(X)=cyz1+ηybzqyz+εz>0 for y21<y<y11 or y12<y<y22. Therefore, the Filippov system (2.4) always comprises two sliding segments, which can be obtained as

    Σ1s={(y,z)R2+|y21<y<y11,z=ET},Σ2s={(y,z)R2+|y12<y<y22,z=ET}. (3.2)

    Naturally, the crossing region we can get is Σc={(y,z)R2+|0<y<y21, or y11<y<y12, or y>y22,z=ET}. Notably, every trajectory within the segment {(y,z)R2+|0<y<y21 or y>y22,z=ET} will intersect the z=ET line, moving from region S1 to S2. Similarly, the trajectory within the segment {(y,z)R2+|y11<y<y12,z=ET} will cross the z=ET line, transitioning from region S2 to S1.

    The Filippov convex method is employed in this study to analyze the sliding domain and sliding mode dynamics of the switching system (2.4). According to Definition 2.2, we have

    dXdt=FS(X)=(1λ)FS1(X)+λFS2(X). (3.3)

    By a straightforward calculation, one can get

    HX,FS1(X)=cyz1+ηybzqyz,HX,FS1(X)FS2(X)=εz. (3.4)

    It follows that

    λ=cyz1+ηybzqyzεz=qηy2(cqbη)y+bε(1+ηy). (3.5)

    Therefore, the dynamic equation of the switching system (2.4) on the sliding mode domain is

    {dydt=ry(1yK)aypyET,dzdt=0. (3.6)

    There exists one positive equilibrium Ec=(yc,ET), where yc=K(1a+pETr). We can easily obtain that r>a+pET. According to Definition 2.2, the equilibrium Ec is referred to as a pseudo-equilibrium.

    When y21<yc<y11, we have

    y11yc=rBrB24qbη2qηKr+2qηK(a+pET)2qηr>0, (3.7)

    and

    ycy21=2qηK[r(a+pET)]r(DD24qη(bε))2qηr>0. (3.8)

    Clearly, y21<yc<y11 is equivalent to

    rapr(BB24qbη)2qpηK<ET<rapr(DD24qη(bε))2qpηK, (3.9)

    (i.e.,z11<ET<z21). Thus, the equilibrium Ec is located on the sliding segment Σ1s when z11<ET<z21. It can be readily confirmed that cyz/(1+hy)<0 holds on the segment Σ2s. Similariy, if y12<yc<y22, we conclude that

    rapr(D+D24qη(bε))2qpηK<ET<rapr(B+B24qbη)2qpηK, (3.10)

    (i.e.,z22<ET<z12). Under this circumstance, the pseudo-equilibrium Ec is located on the sliding segment Σ2s={(y,z)|y12<y<y22,z=ET} for z22<ET<z12, meanwhile, we can get cyz/(1+hy)>0 holds on the segment Σ1s.

    Theorem 3.1. If z11<ET<z21, system (2.4) has one pseudo-equilibrium Ec=(K(1a+pETr),ET) on the sliding segment Σ1s, which is always LAS when it exists; analogously, if z22<ET<z12, then pseudo-equilibrium Ec is LAS on the sliding segment Σ2s.

    Proof. Without loss of generality, we only consider the proof for the first case. Let y=ry(1yK)aypyz.=g(y). Substituting H=zET=0 into the g(y), we will get g(y)=rKy2+(rapET)y. Based on the function g(y), we know g(y21)>0,g(y11)<0. Further, we note that y=g(y), then g(y)=2rKy+(rapET). Naturally g(yc)=2rKK(1a+pETr)+(rapET)=r+a+pET<0, which implies that Ec is LAS. Thus, the equilibrium Ec is locally stable provided it is feasible. Likewise, we can use a similar method to prove Ec is LAS on the Σ2s.

    This part focuses on examining the global dynamics of a switching system. To certify the global stability of the equilibrium of the system (2.4), it is necessary to rule out the presence of limit cycles. Firstly, we let the Dulac function be V(y,z)=1/yz. For subsystem Si(i=1,2), this gives y(V(y,z)dydt)+z(V(y,z)dzdt)=rzK<0. Based on the Dulac-Bendixson criterion, it can be concluded that there are no limit cycles present. Consequently, we can derive the following Lemma 4.1.

    Lemma 4.1. There exists no limit cycle that is entirely situated within the region Si(i=1,2).

    Next, we will exclude limit cycles that intersect with the sliding segment or surrounding the whole sliding segment. Note that this exclusion is necessary for us to follow up with better explanations.

    Lemma 4.2. There does not exist a limit cycle that includes a portion of the sliding segment.

    Proof. We need to establish the proofs of Lemma 4.2 for the cases ET>z21, z11<ET<z21, z12<ET<z11, z22<ET<z12, and 0<ET<z22.

    If ET>z21, the absence of pseudo-equilibrium is deduced from the demonstration of Theorem 3.1, which indicates the presence of dy/dt<0 on the sliding segments Σis(i=1,2) under such circumstances. Therefore, any trajectory reaching Σ1s or Σ2s will approach the boundary points (y21,ET), and E21 is a real stable node. Note that (y21,ET) is visible Σ-fold points of subsystem S2 (see Definition 2.4 in Section 2). Thus, the trajectory initiating at (y21,ET) tends to either approach the stable state E21 directly or in a spiral manner [shown in Figure 1(a)], without touching the switching line again. Therefore, there are no closed orbits that include any part of the sliding segment.

    Figure 1.  The blue lines represent possible closed tracks that contain a portion of the sliding segment.

    If z11<ET<z21, we know that the pseudo-equilibrium Ec is LAS on the segment Σ1s (see Theorem 3.1 in Section 3) under this scenario, which means the nonexistence of a limit cycle that contains part of the sliding segment Σ1s. Beyond that, there is dy/dt<0 on the segment {(y,z)|y12<y<y22,z=ET} when z11<ET<z21. This implies that the orbits reaching sliding segment Σ2s firstly slide towards the boundary point (y12,ET), which is a visible Σ-fold point as well, enter into the S1, and then tend to Ec. Therefore, there exists no limit cycle incorporating any portion of the sliding segment.

    If z12<ET<z11, there exists one real stable equilibrium E11 in region S1. Thus, we can employ a way similar to that applied in the first case to demonstrate the conclusion [shown in Figure 1(b)].

    If z22<ET<z12, we have that pseudo-equilibrium Ec is LAS on the sliding segment Σ2s. We get dy/dt>0 on the segment Σ1s in this case. Clearly, the proof process is similar to the second case, so we have omitted here.

    If 0<ET<z22, we know that there is no pseudo-equilibrium, and dy/dt>0 holds on the sliding segments Σis(i=1,2), since there exists a stable equilibrium E1, and (y22,ET) is visible Σ-fold point. Thus, the orbits starting from segments Σis(i=1,2) move from the left to the right along the sliding line to the boundary point (y22,ET). Then, they proceed into region S1 and eventually converge to E1, without experiencing hitting the switching line z=ET again. Thus, the proof for Lemma 4.2 is thereby completed.

    Significantly, the following lemma is similar to previous studies [37,38], which is obtained by constructing a cycle around the sliding segment and then using the method of counter-evidence to draw a contradiction.

    Lemma 4.3. There exists no closed orbit containing the whole sliding segment.

    Combined with analysis in Section 2, we obtain the two sets of key parameters, i.e., R0,Rc1,Rc2, and c2,c4,c,c,c,c. They are the crucial elements that determine the dynamic behavior of the system (2.4). Next, we will discuss the global dynamics of the proposed piecewise system based on the relationships between the parameters mentioned earlier. Considering that there exists only one uninfected equilibrium E0 for both subsystem S1 and S2 when R0<1, we will not delve further into it. Here, we will focus on the following situations:

    Case(a): R0>Rc1>Rc2>1,

    Case(b): Rc1>Rc2>R0>1,

    Case(c): Rc1>R0>Rc2>1.

    The global dynamics for Case (a) are the main focus of this section. Note that the analysis methods for the three cases are analogous, thus we have omitted detailed proofs for the other cases. According to the results in Section 2, it can be seen that the relationship between immune intensity c and parameters c2,c4,c,c,c,c have a significant impact on the dynamics of the system (2.4). Through direct analysis, we will consider the under situations:

    c4<c<c2;c2<c<c;c<c<c;c<c<c;c<c<c;c>c. (4.1)

    To understand the dynamics of the system (2.4) more comprehensively, we present the stabilities of various equilibriums completely in Table 3, considering that the dynamics of the system also depend on the relationship between threshold ET and z11,z12,z21, and z22. Thus, we have the following threshold levels:

    ET>z21;z11<ET<z21;z12<ET<z11;z22<ET<z12;0<ET<z22. (4.2)
    Table 3.  The stability of equilibrium points for subsystem S1 and S2 when R0>Rc1>Rc2>1.
    Condition E11=E21=E1 E11 E12 E21 E22
    c4<c<c2 LAS LAS US
    c2<c<c LAS LAS US LAS US
    c<c<c LAS LAS US LAS US
    c<c<c US LAS US LAS US
    c<c<c US LAS US LAS
    c<c US LAS LAS

     | Show Table
    DownLoad: CSV

    In such a case, if equilibriums E11,E12,E21, and E22 exist, it can be noted that E11 and E12 are virtual, whereas E21 and E22 are real, with E21 being LAS. We will examine the following six cases in the light of the connections between c and c4,c2,c,c,c,c.

    Subcase (ⅰ): Assume c4<c<c2, here we know E1 is LAS. Note that equilibria E11 and E12 do not exist under this scenario. All the orbits in S1 will reach the switching line z=ET within a finite amount of time, then firstly enter S2 and ultimately approach either E21 or E1 [shown in Figure 2(a)], contingent upon their initial positions. Thus, the E21 and E1 are bistable in this particular scenario.

    Figure 2.  Dynamical behavior of the system (2.4) for Case(a1).
    Note: The purple and blue lines represent trajectories that finally tend to the equilibriums E21 and E1, respectively. Parameters are: r=6, K=6, p=1, q=1, b=1 and (a)η=0.55, a=3, ε=0.12, c=2.9, ET=2.5; (b)η=0.5, a=3, ε=0.12, c=2.92, ET=2.8; (c)η=0.57, a=3, ε=0.13, c=3.4, ET=2.8; (d)η=0.75, a=2.68, ε=0.1, c=4.55, ET=3.3; (e)η=0.75, a=2.67, ε=0.1, c=6.68, ET=4; (f)η=0.9, a=3, ε=0.1, c=6.97, ET=4.

    Subcase (ⅱ): Assume c2<c<c, we have immune-free equilibrium E1 is LAS in subsystem S2. According to Lemma 4.2, there exists dy/dt<0 on the Σis(i=1,2) when ET exceeds z21. Therefore, all the orbits of subsystem S1 will slide from right to left to the (y21,ET) or (y12,ET) when they reach the sliding segments, and finally tend to E21. Hence, E21 and E1 are bistable [illustrated in Figure 2(b)].

    Subcase (ⅲ): Assume c<c<c, here we have equilibrium E1, real equilibrium E21 are LAS. In this subcase, system (2.4) has the same bistable behavior as the previous case [shown in Figure 2(c)].

    Subcase (ⅳ): Assume c<c<c, we get that E1 is US, and there is only one stable equilibrium E21. Thus, any orbit starting from region S1 firstly crosses the switching line z=ET and enters S2, following the dynamics of S2 tends to E21. Additionally, Lemmas 4.1–4.3 confirms the absence of a limit cycle, implying that all trajectories ultimately converge to E21. Therefore, it can be concluded that the equilibrium E21 is GAS [shown in Figure 2(d)].

    Subcase (ⅴ): Assume c<c<c. In such a subcase, we know equilibrium E22 does not exist. In consideration of the nonexistence of the limit cycle, E21 becomes a glocally stable equilibrium [shown in Figure 2(e)].

    Subcase (ⅵ): Assume c>c. Under this scenario, we know equilibria E12 and E22 do not exist. That is, there exists not any other stable equilibrium other than E21. Considering that the existence of the limit cycle is excluded, endemic equilibrium E21 is GAS [shown in Figure 2(f)]. The dynamics of the system (2.4) can be summarized below when ET>z21.

    Theorem 4.1. Suppose ET>z21, it can be deduced that both E21 and E1 are bistable for c4<c<c2,c2<c<c,c<c<c; positive equilibrium E21 is GAS for c<c<c, c<c<c and c>c.

    In such a case, if equilibriums E11,E12,E21, and E22 exist, we have E11, E12, E21 are virtual, while E22 is real but US. Meanwhile, our analysis reveals the occurrence of sliding mode and the emergence of pseudo-equilibrium within the sliding segment Σ1s={(y,z)|y21<y<y11,z=ET}. By Theorem 3.1, we know that the pseudo-equilibrium Ec is LAS when it exists. Likewise, we will analyze the following six scenarios.

    Subcase (ⅰ): Assume c4<c<c2. We know equilibria E11 and E12 do not exist, then we have omitted the description for this case.

    Subcase (ⅱ): Assume c2<c<c. In such a subcase, E1 is LAS in the subsystem S2 and the pseudo-equilibrium will appear on the sliding segment Σ1s. Thus, the partial orbits starting from region S1 will follow the dynamics of S1 to the sliding segment {(y,z)|y21<y<yc,z=ET}, whereas partial trajectories starting from subsystem S2 will arrive at the segment {(y,z)|yc<y<y11,z=ET} along the S2, depending on the initial point, and both types of orbits will eventually converge toward pseudo-equilibrium Ec. Therefore, we conclude that Ec and E1 are bistable [shown in Figure 3(a)].

    Figure 3.  Dynamical behavior of the system (2.4) for Case(a2).
    Note: The purple and blue lines represent trajectories that finally tend to the equilibriums Ec and E1, respectively. Parameters are: r=6, K=6, p=1, q=1, b=1 and (a)η=0.5, a=3, ε=0.12, c=3, ET=2.1; (b)η=0.75, a=3, ε=0.32, c=3.9, ET=2.5; (c)η=0.75, a=2.78, ε=0.11, c=4.48, ET=2.8; (d)η=0.75, a=2.67, ε=0.1, c=6.7, ET=2.95; (e)η=0.85, a=3.02, ε=0.15, c=6.96, ET=2.8.

    Subcase (ⅲ): Assume c<c<c. In such a subcase, we get that both pseudo-equilibrium Ec on the sliding segment Σ1s and equilibrium E1 are LAS. Thus, we can obtain the coincident conclusion by using similar ways of discussion. That is, the orbits will either go to Ec or tend to E1 along the subsystem S1 and S2, respectively [shown in Figure 3(b)].

    Subcase (ⅳ): Assume c<c<c. In such a subcase, Ec is the only stable equilibrium for the system (2.4). Our findings reveal that all trajectories intersecting with the line z=ET and following the sliding segment Σ1s reach the pseudo-equilibrium Ec. Considering that a limit cycle does not exist for the entire system, we can conclude that Ec is GAS [illustrated in Figure 3(c)].

    Subcase (ⅴ): Assume c<c<c. In such a subcase, we know E22 does not exist and the pseudo-equilibrium Ec is LAS. Here, we have immune-free equilibrium E1 is US. Equally, system (2.4) does not exist any limit cycle. Then the equilibrium Ec is GAS [shown in Figure 3(d)].

    Subcase (ⅵ): Assume c>c. Under this condition, equilibria E12 and E22 do not exist. There is only one stable equilibrium Ec in the switching system (2.4). Considering the exclusion of closed orbit, then Ec is GAS [illustrated in Figure 3(e)]. Hence, we summarize the aforementioned conclusion of system (2.4) to the following when z11<ET<z21.

    Theorem 4.2. Suppose z11<ET<z21, we can conclude that system (2.4) has bistable behavior, i.e., immune-free equilibrium E1 and pseudo-equilibrium Ec are LAS for c2<c<c,c<c<c; equilibrium Ec is GAS for c<c<c, c<c<c and c>c.

    In such a case, if equilibriums E11,E12,E21,E22 exist, we get E12 and E21 are virtual, but E11 and E22 are real, where E11 is LAS in the S1. We prove the existence of sliding mode but there is no pseudo-equilibrium. Next, we will analyze the stability of equilibria based on the connections between c and c4,c2,c,c,c,c.

    Subcase (ⅰ): Assume c4<c<c2. Under this scenario, it follows from Section 2 that the two equilibria E11 and E12 are not feasible. So we can omit the description for this case.

    Subcase (ⅱ): Assume c2<c<c. In such a subcase, E1 is LAS and E11 is a real and stable equilibrium, since subsystem S1 has only one stable endemic state. Thus, trajectories initiating from S1 will intend to approach the equilibrium E11. In this scenario, the endemic equilibrium E11 can coexist with the immune-free equilibrium E1. That is, system (2.4) has bistable behavior [shown in Figure 4(a)].

    Figure 4.  Dynamical behavior of the system (2.4) for Case(a3).
    Note: The purple and blue lines represent trajectories that finally tend to the equilibriums E11 and E1, respectively. Parameters are: r=6, K=6, p=1, q=1, b=1 and (a)η=0.85, a=3.02, ε=0.15, c=3.96, ET=1.6; (b)η=0.65, a=3, ε=0.12, c=3.7, ET=1; (c)η=0.75, a=2.78, ε=0.13, c=4.48, ET=1.1; (d)η=0.75, a=2.67, ε=0.1, c=6.7, ET=2.

    Subcase (ⅲ): Assume c<c<c. Regarding the presence and stability of the equilibriums, the dynamics exhibited by subsystems S1 and S2 resemble those of the former scenario [shown in Figure 4(b)]. Thus, we get that E11 and E1 are bistable for the Filippov system (2.4).

    Subcase (ⅳ): Assume c<c<c. In this subcase, the equilibrium E21 is virtual and the system (2.4) only exhibits one stable endemic equilibrium E11. As there is no limit cycle, then E11 is GAS [shown in Figure 4(c)].

    Subcase (ⅴ): Assume c<c<c. Analogously, there exists only one stable equilibrium point E11 in subsystem S1. It should be noted that the endemic equilibrium E11 functions as an attractor. We have excluded the existence of limit cycles. Consequently, any orbit starting from region S1 or S2 will approach the equilibrium point E11 [shown in Figure 4(d)]. Thus, the equilibrium E11 is GAS.

    Subcase (ⅵ): Assume c>c. In this scenario, since the equilibria E12 and E22 do not exist, we have omitted the description for this case and we get the following conclusion.

    Theorem 4.3. Suppose z12<ET<z11, we can conclude that immune-free equilibrium E1 and endemic equilibrium E11 are bistable for c2<c<c and c<c<c; equilibrium E11 is GAS for c<c<c and c<c<c.

    In such a case, if equilibriums E11,E12,E21, and E22 exist, we have E21 is virtual, while E11, E12, and E22 are real. Note that both equilibriums E12 and E22 are US. Furthermore, the sliding mode does exist, and the pseudo-equilibrium Ec is LAS on the Σ2s. A similar discussion works for z22<ET<z12.

    Subcase (ⅰ): Assume c4<c<c2, we know equilibria E11 and E12 do not exist according to Section 2. Therefore, we can ignore the explanation of this situation.

    Subcase (ⅱ): Assume c2<c<c. In such a subcase, E1 is LAS and E11 is real and stable in S1. As mentioned above, the pseudo-equilibrium Ec is LAS. From the dynamics of subsystems S2 and S1, it can be deduced that the orbits will either directly reach the E11, E1 or firstly arrive at the line z=ET on the segment {(y,z)|y12<y<y22,z=ET}, then slide to the Ec along sliding segment Σ2s, depending on the initiating points. Hence, as is shown in Figure 5(a), the equilibriums E11, Ec, and E1 are tristable.

    Figure 5.  Dynamical behavior of the system (2.4) for Case(a4).
    Note: The trajectories represented by the purple, green, and blue lines finally tend to the equilibrium points E11, Ec, and E1, respectively. Parameters are: r=6, K=6, p=1, q=1, b=1, and (a)η=0.85, a=3.02, ε=0.15, c=3.96, ET=0.9; (b)η=0.75, a=3, ε=0.32, c=3.6, ET=1; (c)η=0.85, a=2.78, ε=0.12, c=4.9, ET=0.2.

    Subcase (ⅲ): Assume c<c<c. In such a subcase, we get that the equilibrium E1 is LAS, and there exist two equilibria E11 and Ec, which are locally stable in their respective regions. Thus, we can conclude that the dynamic behaviors in this scenario are consistent with the former subcase. That is, system (2.4) has tristable behavior in this case [shown in Figure 5(b)].

    Subcase (ⅳ): Assume c<c<c. Note that the locally stable equilibrium E21 is virtual, then cannot be attained. Part of the trajectories starting from subsystem S1 will approach the equilibrium E11, while certain trajectories will collide on the switching line at finite time, and the locally stable pseudo-equilibrium Ec appears ultimately on the segment Σ2s={(y,z)|y12<y<y22,z=ET}. Hence, they are bistable for the switching system (2.4) [shown in Figure 5(c)].

    Subcase (ⅴ): Assume c<c<c. We know equilibrium E22 does not exist, then we rule this out.

    Subcase (ⅵ): Assume c>c. In such a subcase, we know equilibria E12 and E22 do not exist, so we have omitted the description in this case as well. To sum up, we can derive the conclusion as follows.

    Theorem 4.4. Suppose z22<ET<z12, we can conclude that the real equilibrium E11, pseudo-equilibrium Ec, and the immune-free equilibrium E1 are tristable for c2<c<c and c<c<c; immune-free equilibrium E11 and pseudo-equilibrium Ec are bistable for c<c<c.

    In such a case, if equilibriums E11,E12,E21, and E22 exist, we have E21 and E22 are virtual, but E11, E12 are real, where E11 is LAS in the S1. Under this scenario, there is no pseudo-equilibrium for the Filippov system (2.3). Subsequently, we will analyze the following situations based on the relationships between immune intensity c and c4,c2,c,c,c,c.

    Subcase (ⅰ): Assume c4<c<c2. In this condition, we get that equilibria E11 and E12 do not exist on the basis of the discussion of Section 2. Note that the locally stable equilibrium E21 is virtual. Thus, there is not any other stable equilibrium besides E1, as all the possible limit cycles have been excluded. Hence, we have E1 is GAS [shown in Figure 6(a)].

    Figure 6.  Dynamical behavior of the system (2.4) for Case(a5).
    Note: The purple and blue lines represent trajectories that finally tend to the equilibriums E11 and E1, respectively. Parameters are: r=6, K=6, p=1, q=1, b=1, and (a)η=0.65, a=3.02, ε=0.15, c=3.1, ET=0.6; (b)η=0.85, a=3.02, ε=0.15, c=3.7, ET=0.8; (c)η=0.65, a=3.02, ε=0.15, c=3.7, ET=0.08; (d)η=0.75, a=2.78, ε=0.13, c=4.5, ET=0.04.

    Subcase (ⅱ): Assume c2<c<c. In such a subcase, E1 is LAS and E11 is a real and stable equilibrium. However, E21 is virtual in S1. Thus, positive equilibrium E11 and immune-free equilibrium E1 are bistable for c2<c<c being satisfied [shown in Figure 6(b)].

    Subcase (ⅲ): Assume c<c<c. We know that equilibria E11 and E1 are LAS as well. Thus, the dynamics of this case are similar to the former, i.e., the bistable behavior occurs [shown in Figure 6(c)].

    Subcase (ⅳ): Assume c<c<c. In such a subcase, note that locally stable equilibrium E21 is virtual and then cannot be attained. There exists only one stable equilibrium point E11 in subsystem S1. As there is no limit cycle, we obtain that the equilibrium E11 is GAS [illustrated in Figure 6(d)].

    Subcase (ⅴ): Assume c<c<c. In such a subcase, we know that equilibrium E22 does not exist, so we have ignored the description of this situation.

    Subcase (ⅵ): Assume c>c. In such a subcase, both E12 and E22 do not exist, therefore, the explanation for this case is omitted. Consequently, we arrive at the subsequent conclusion.

    Theorem 4.5. Suppose 0<ET<z22, we can conclude that immune-free equilibrium E1 is GAS for c4<c<c2; the real equilibrium E11 and immune-free equilibrium E1 are bistable for c2<c<c and c<c<c; the equilibrium E11 is GAS for c<c<c.

    In fact, extensive discussions have been conducted on the stability of various equilibriums for the switching system (2.4) under Case(a). Furthermore, Table 4 provides a comprehensive summary of the global dynamics associated with these specific cases.

    Table 4.  Existence and stability of the equilibria for the Filippov system (2.4) when R0>Rc1>Rc2>1.
    Threshold value Immune intensity E1 E11 E12 E21 E22 Ec Global stability
    ET>z21 c4<c<c2 LAS LAS(R) US Bistable
    c2<c<c LAS LAS(V) US LAS(R) US Bistable
    c<c<c LAS LAS(V) US LAS(R) US Bistable
    c<c<c US LAS(V) US LAS(R) US E21 GAS
    c<c<c US LAS(V) US LAS(R) E21 GAS
    c<c US LAS(V) LAS(R) E21 GAS
    z11<ET<z21 c2<c<c LAS LAS(V) US LAS(V) US LAS Bistable
    c<c<c LAS LAS(V) US LAS(V) US LAS Bistable
    c<c<c US LAS(V) US LAS(V) US LAS Ec GAS
    c<c<c US LAS(V) US LAS(V) LAS Ec GAS
    c<c US LAS(V) LAS(V) LAS Ec GAS
    z12<ET<z11 c2<c<c LAS LAS(R) US LAS(V) US Bistable
    c<c<c LAS LAS(R) US LAS(V) US Bistable
    c<c<c US LAS(R) US LAS(V) US E11 GAS
    c<c<c US LAS(R) US LAS(V) E11 GAS
    z22<ET<z12 c2<c<c LAS LAS(R) US LAS(V) US LAS Tristable
    c<c<c LAS LAS(R) US LAS(V) US LAS Tristable
    c<c<c US LAS(R) US LAS(V) US LAS Bistable
    0<ET<z22 c4<c<c2 LAS LAS(V) US E1 GAS
    c2<c<c LAS LAS(R) US LAS(V) US Bistable
    c<c<c US LAS(R) US LAS(V) US E11 GAS

     | Show Table
    DownLoad: CSV

    Notably, the collision of pseudo-equilibrium, tangent point, and regular equilibrium (or tangent point and regular equilibrium) in switching systems occurs when ET reaches a critical value, leading to boundary equilibrium bifurcations on the discontinuity surface [as shown in Figure 7]. The understanding and analysis of these boundary equilibrium bifurcations are crucial in studying the dynamical behavior of the Filippov system. To verify the boundary equilibrium bifurcation, we select ET as the bifurcation parameter while keeping all other parameters constant. Detailed explanations of the boundary equilibrium and the tangent point are shown in Definitions 2.3 and 2.5.

    Figure 7.  Boundary equilibrium bifurcations for the switching system (2.4).
    Note: Here, we choose ET as a bifurcation parameter and other parameter values are fixed as r=6, K=6, p=1, q=1, b=1, η=0.5, a=3, ε=0.12, c=2.92 and (a) ET=2.5; (b) ET=2.176; (c) ET=1.9; (d) ET=1.7081; (e) ET=1.55; (f) ET=1.4519; (g) ET=0.98; (h) ET=0.864; (i) ET=0.64.

    Boundary equilibrium of the Filippov system (2.4) satisfies

    ry(1yK)aypyz=0,cyz1+ηybzqyz+ϕεz=0,zET=0, (5.1)

    where ϕ=0 or ϕ=1. By solving the equations provided in (5.1), it is possible to obtain four potential boundary equilibria

    E11B=(y11,ET),E12B=(y12,ET),E21B=(y21,ET),E22B=(y22,ET). (5.2)

    Tangent points of the Filippov system (2.4) satisfy

    cyz1+ηybzqyz+ϕεz=0,zET=0. (5.3)

    Thus, the potential tangent points can be denoted as

    T11=(y11,ET),T12=(y12,ET),T21=(y21,ET),T22=(y22,ET), (5.4)

    which are the solutions of (5.4) corresponding to ϕ=0 and ϕ=1.

    Figure 7 examines a series of boundary equilibrium bifurcations when c2<c<c. In this case, both subsystems have two positive equilibria. The real and stable equilibrium E21 coexists simultaneously with the visible tangent point T21 when ET>z21 [shown in Figure 7(a)]. As ET decreases from ET>z21 to z21, E21 collides with T21 [shown in Figure 7(b)]. With the threshold ET decreasing further to z11<ET<z21, a stable pseudo-equilibrium Ec emerges and T21 transforms into an invisible tangent point [as depicted in Figure 7(c)]. This bifurcation exhibits the progress of the formation of Ec. Furthermore, boundary bifurcation takes place again when ET through the critical value z11. This case results in the collision of the tangent point T11, the equilibrium point E11 with the pseudo-equilibrium point Ec [as depicted in Figure 7(d)]. Subsequently, the Ec vanishes, and the stable point E11 transforms into the local attractor [as illustrated in Figure 7(e)]. When ET drops consistently until z12, the third boundary bifurcation takes place, leading to the collision of the visible tangent point T12 with the equilibriums E12 [as depicted in Figure 7(f)].

    Provided ET continues to decrease until z22<ET<z12, a locally stable pseudo-equilibrium Ec appears [as shown in Figure 7(g)] and a tristable phenomenon (Ec, E11, and the immune-free equilibrium E1) occurs. When ET passes E22, the fourth boundary equilibrium bifurcation occurs. In this scenario, the pseudo-equilibrium Ec will collide with the equilibrium point E22 and tangent point T22 if ET=z22 [illustrated in Figure 7(h)]. However, as the threshold ET continues to decrease, the equilibrium Ec disappears, and the tangent point T22 becomes invisible [illustrated in Figure 7(i)]. Here, the equilibriums E1 and E11 exhibit bistability under this scenario.

    In order to stabilize the HIV viral loads and effector cell counts within the required predetermined level, it is crucial to implement a control strategy for the switching system (2.4) by setting an appropriate threshold ET. The dynamics of the system are influenced by two key parameters: The immune intensity c and the inhibition of the virus on the proliferation of immune cells η. Therefore, it is important to study the impact of these parameters on the system's dynamics. Note that the parameters in this study are based on the findings of Komarova[33] and colleagues. A direct calculation reveals that the bistable interval is (2.7666, 3.2333) [shown in Figure 8(a)]. From this figure, it is evident that system (2.4) has the potential to have either one or two nontrivial LAS equilibria depending on the value of c. In detail, two stable equilibriums E21 and E21 coexist when c4<c<c. As established in Section 2, there is a unique LAS equilibrium E21 if c>c. It is important to note that a saddle-node bifurcation occurs at c=c4. Generally, a longer bistable interval implies a wider range of variation for the proliferation coefficient c of immune cells. In this context, a lower viral inhibition intensity η [shown in Figure 8(b)] is more advantageous for immune control. This indicates the necessity of developing medications aimed at diminishing the viral inhibitory effect on immune cells. The phase portrait of this system reveals that both variables y and z will gradually tend to a stable value over time t changed [shown in Figures 8(c) and (d)]. In subsystem S2, the combination of antiretroviral therapy and immunotherapy not only controlled the number of viruses better but also stabilized the immune cell count at a more reliable level than the free system, as can be seen in Figures 8(e) and (f).

    Figure 8.  (a) Saddle–node bifurcation diagram and bistable of the subsystem S2, where r=6, K=6, p=1, q=1, b=1, η=0.5, a=3, ε=0.12 such that c2=2.7666, c=3.2333, where the LAS equilibrium of viral load is depicted by the solid line, while the dashed line illustrates the US equilibrium; (b) The impact of the intensity of virus inhibition (η) on the duration of the bistable interval; (c) and (d) Parameters are η=0.55, a=3, ε=0.12, c=2.9, the other parameter values are the same to those of (a). At this point, the system will gradually tend to stabilize; (e) and (f) The dynamic behaviors of virus and immune cells in the system (2.4) within time.

    Given the immunosuppressive HIV infection model[32,33,34], it is suggested that the threshold policy control (TPC) method for treating infected patients should be based on the number of immune cells. Thus, we propose a piecewise immunosuppressive infection system. We call model (2.4) a discontinuous right-hand side dynamical system under TPC, which consists of two subsystems. Specifically, it is recommended to initiate a combination of antiretroviral therapy and immune therapy when the value drops below a certain threshold ET, which includes the usage of antiretroviral medications and interleukin (IL)-2. This leads to the emergence of a nonsmooth system. Unlike [31], we consider the logical growth of HIV rather than linear growth in this paper. Some clinical facts indicate that the saturated growth of HIV is reasonable.

    Initially, we provide a concise overview of the dynamics exhibited by the two subsystems. Through the subsystems Si(i=1,2), we derive the thresholds R0, Rc1, and Rc2. It becomes evident that R0 plays a pivotal part in determining the eradication of the virus. We also obtain the post-treatment control thresholds c2(c4) and the elite control threshold c(c) for subsystems S1 (S2). According to [34], there exists a bistable behavior between these two threshold intervals. The sliding dynamics and sliding domain of the system (2.4) are studied in the subsequent analysis. Our purpose is to demonstrate the existence of two sliding segments Σis(i=1,2). By employing the Filippov convex approach, we investigate the possibility and local asymptotic stability of the pseudo-equilibrium Ec on the sliding segment Σ1s under the z11<ET<z21, or on the sliding segment Σ2s under the z22<ET<z12. Significantly, we have primarily focused on Case (a) and discussed the global dynamics of the system in this paper. To investigate the global dynamic behavior of the system, we have excluded the existence of three types of limit cycles. It is important to understand the relationship not only among R0,Rc1,Rc2, and 1 but also among immune intensity c and c4,c2,c,c,c,c. Subsequently, the bifurcation theories were utilized to address the dynamics of sliding mode and local sliding bifurcations.

    The analysis reveals that the system can demonstrate diverse and complex dynamic behaviors: (ⅰ) One of the equilibria in the system is GAS, which can manifest as the immune-free equilibrium E1, pseudo-equilibrium Ec, or even as the positive equilibrium E11 or E21 within subsystems S1 or S2; (ⅱ) There are two possible equilibria in this system that exhibit bistability, namely the immune-free equilibrium E1 and equilibrium E21 (or Ec or E11), or the positive equilibrium E11, which is bistable alongside the pseudo-equilibrium Ec; (ⅳ) Three equilibria are tristable, i.e., immune-free equilibrium E1, positive equilibrium E11, and the pseudo-equilibrium Ec are stable for z22<ET<z12 and c2<c<c. Our work demonstrates that the utilization of effector cell-guided therapy leads to an expansion of the controllable area of initial values for patients, generating a more complex Filippov dynamics system when compared with [35]. Interestingly, we find that there exists an optimal threshold interval for immune intensity that can maximize the controllable area of initial values. This highlights the importance of considering the effects of effector cell-guided therapy and immune intensity when studying the dynamics of the switching system. It suggests that maximizing the controllable area of initial values can potentially improve the effectiveness of treatment strategies for patients.

    In this paper, the existence of three types of equilibria including pseudo-equilibrium is explored. These equilibria can exhibit bistability or tristability, meaning that the HIV viral loads and effector cell counts can be stabilized at a preset level. Achieving these stable states depends on factors such as the threshold level, immune intensity, and the initial values of the system. Consequently, determining the optimal strategy for immune intensity and the threshold conditions should still take into account the individual characteristics of the patients. In the case of boundary H(X), the selection of parameter values is crucial in stabilizing different equilibria within the system. From a biological standpoint, employing rational control intensity and intervention is highly effective in ensuring the control and management of diseases.

    Although our research has an impact on HIV disease control, it is still insufficient. We only consider the relationship between the number of effector cells and the threshold level to construct switching conditions. The actual disease control strategy should also take into account the change rate of effector cell count, which will be our next work. By considering these factors, we aim to further provide insights into the effectiveness and impact of this treatment approach on the virus-immune system dynamics. This mathematical model could potentially contribute to the improvement of treatment strategies for viral infections.

    The authors declare that no Artificial Intelligence (AI) tools were used in the creation of this article.

    This work was supported by The National Natural Science Foundation of China (Grant No. 12261033).

    The authors would like to thank the editor and anonymous referees for their valuable comments and suggestions, which have led to an improvement of the paper.

    The authors declare no conflict of interest.


    Acknowledgments



    There is no financial support for conducting the research and preparing the article.

    Conflict of interest



    James C.L. Chow is an editorial board member for AIMS Biophysics and was not involved in the editorial review or the decision to publish this article. The author has no potential conflict of interest on financial or commercial matters associated with this study.

    [1] Chow JCL (2017) Application of nanoparticle materials in radiation therapy. Handbook of Ecomaterials.Springer 3661-3681. https://doi.org/10.1007/978-3-319-68255-6_111
    [2] Chow JCL (2020) Recent progress of gold nanomaterials in cancer therapy. Handbook of Nanomaterials and Nanocomposites for Energy and Environmental Applications.Springer 1-30. https://doi.org/10.1007/978-3-030-36268-3_2
    [3] Dippong T (2024) Innovative nanomaterial properties and applications in chemistry, physics, medicine, or environment. Nanomaterials 14: 145. https://doi.org/10.3390/nano14020145
    [4] Yang Z, Chen H, Yang P, et al. (2022) Nano-oxygenated hydrogels for locally and permeably hypoxia relieving to heal chronic wounds. Biomaterials 282: 121401. https://doi.org/10.1016/j.biomaterials.2022.121401
    [5] Shi L, Song D, Meng C, et al. (2024) Opportunities and challenges of engineered exosomes for diabetic wound healing. Giant 18: 100251. https://doi.org/10.1016/j.giant.2024.100251
    [6] Fu W, Sun S, Cheng Y, et al. (2024) Opportunities and challenges of nanomaterials in wound healing: Advances, mechanisms, and perspectives. Chem Eng J 495: 153640. https://doi.org/10.1016/j.cej.2024.153640
    [7] Siddique S, Chow JCL (2020) Application of nanomaterials in biomedical imaging and cancer therapy. Nanomaterials 10: 1700. https://doi.org/10.3390/nano10091700
    [8] Trucillo P (2024) Biomaterials for drug delivery and human applications. Materials 17: 456. https://doi.org/10.3390/ma17020456
    [9] Staffurth J (2010) A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 22: 643-657. https://doi.org/10.1016/j.clon.2010.06.013
    [10] Brito CL, Silva JV, Gonzaga RV, et al. (2024) A review on carbon nanotubes family of nanomaterials and their health field. ACS Omega 9: 8687-8708. https://doi.org/10.1021/acsomega.3c08824
    [11] Hu J, Dong M (2024) Recent advances in two-dimensional nanomaterials for sustainable wearable electronic devices. J Nanobiotechnol 22: 63. https://doi.org/10.1186/s12951-023-02274-7
    [12] Rehmanullah MZ, Inayat N, Majeed A (2020) Application of nanoparticles in agriculture as fertilizers and pesticides: challenges and opportunities. New Frontiers in Stress Management for Durable Agriculture : 281-293. https://doi.org/10.1007/978-981-15-1322-0_17
    [13] Petersen EJ, Nelson BC (2010) Mechanisms and measurements of nanomaterial-induced oxidative damage to DNA. Anal Bioanal Chem 398: 613-650. https://doi.org/10.1007/s00216-010-3881-7
    [14] Moore JA, Chow JCL (2021) Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. Nano Express 2: 022001. https://doi.org/10.1088/2632-959X/abddd3
    [15] Barua S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 9: 223-243. https://doi.org/10.1016/j.nantod.2014.04.008
    [16] Yan L, Gu Z, Zhao Y (2013) Chemical mechanisms of the toxicological properties of nanomaterials: generation of intracellular reactive oxygen species. Chem Asian J 8: 2342-2353. https://doi.org/10.1002/asia.201300542
    [17] Ruan C, Su K, Zhao D, et al. (2021) Nanomaterials for tumor hypoxia relief to improve the efficacy of ROS-generated cancer therapy. Front Chem 9: 649158. https://doi.org/10.3389/fchem.2021.649158
    [18] Fu PP, Xia Q, Hwang HM, et al. (2014) Mechanisms of nanotoxicity: generation of reactive oxygen species. J Food Drug Anal 22: 64-75. https://doi.org/10.1016/j.jfda.2014.01.005
    [19] Chow JCL (2016) Photon and electron interactions with gold nanoparticles: a Monte Carlo study on gold nanoparticle-enhanced radiotherapy. Nan Med Imag 8: 45-70. https://doi.org/10.1016/B978-0-323-41736-5.00002-9
    [20] Chow JCL, Santiago CA (2023) DNA damage of iron-gold nanoparticle heterojunction irradiated by kV photon beams: a Monte Carlo study. Appl Sci 13: 8942. https://doi.org/10.3390/app13158942
    [21] Santiago CA, Chow JCL (2023) Variations in gold nanoparticle size on DNA damage: a Monte Carlo study based on a multiple-particle model using electron beams. Appl Sci 13: 4916. https://doi.org/10.3390/app13084916
    [22] Kalyane D, Raval N, Maheshwari R, et al. (2019) Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C 98: 1252-1276. https://doi.org/10.1016/j.msec.2019.01.066
    [23] Martelli S, Chow JCL (2020) Dose enhancement for the flattening-filter-free and flattening-filter X-ray beams in nanoparticle-enhanced radiotherapy: a Monte Carlo phantom study. Nanomaterials 10: 637. https://doi.org/10.3390/nano10040637
    [24] Chow JCL (2022) Special issue: application of nanomaterials in biomedical imaging and cancer therapy. Nanomaterials 12: 726. https://doi.org/10.3390/nano12050726
    [25] Thongkumkoon P, Sangwijit K, Chaiwong C, et al. (2014) Direct nanomaterial-DNA contact effects on DNA and mutation induction. Toxicol Lett 226: 90-97. https://doi.org/10.1016/j.toxlet.2014.01.036
    [26] Bhabra G, Sood A, Fisher B, et al. (2009) Nanoparticles can cause DNA damage across a cellular barrier. Nat Nanotechnol 4: 876-883. https://doi.org/10.1038/nnano.2009.313
    [27] Wan R., Mo Y, Feng L, et al. (2012) DNA damage caused by metal nanoparticles: involvement of oxidative stress and activation of ATM. Chem Res Toxicol 25: 1402-1411. https://doi.org/10.1021/tx200513t
    [28] Zijno A, De Angelis I, De Berardis B, et al. (2015) Different mechanisms are involved in oxidative DNA damage and genotoxicity induction by ZnO and TiO2 nanoparticles in human colon carcinoma cells. Toxicol Vitrp 29: 1503-1512. https://doi.org/10.1016/j.tiv.2015.06.009
    [29] Hahm JY, Park J, Jang ES, et al. (2022) 8-Oxoguanine: from oxidative damage to epigenetic and epitranscriptional modification. Exp Mol Med 54: 1626-1642. https://doi.org/10.1038/s12276-022-00822-z
    [30] Letavayová L, Marková E, Hermanská K, et al. (2006) Relative contribution of homologous recombination and non-homologous end-joining to DNA double-strand break repair after oxidative stress in Saccharomyces cerevisiae. DNA Repair 5: 602-610. https://doi.org/10.1016/j.dnarep.2006.01.004
    [31] Cadet J, Douki T, Gasparutto D, et al. (2003) Oxidative damage to DNA: formation, measurement, and biochemical features. Mutat Res/Fund Mol M 531: 5-23. https://doi.org/10.1016/j.mrfmmm.2003.09.001
    [32] Encinas-Gimenez M, Martin-Duque P, Martín-Pardillos A (2024) Cellular alterations due to direct and indirect interaction of nanomaterials with nucleic acids. Int J Mol Sci 25: 1983. https://doi.org/10.3390/ijms25041983
    [33] Li X, Liu W, Sun L, et al. (2015) Effects of physicochemical properties of nanomaterials on their toxicity. J Biomed Mater Res A 103: 2499-2507. https://doi.org/10.1002/jbm.a.35384
    [34] Li Y, Lian Y, Zhang LT, et al. (2016) Cell and nanoparticle transport in tumour microvasculature: the role of size, shape and surface functionality of nanoparticles. Interface Focus 6: 20150086. https://doi.org/10.1098/rsfs.2015.0086
    [35] Schaeublin NM, Braydich-Stolle LK, Schrand AM, et al. (2011) Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale 3: 410-420. https://doi.org/10.1039/C0NR00478B
    [36] Siddique S, Chow JCL (2022) Recent advances in functionalized nanoparticles in cancer theranostics. Nanomaterials 12: 2826. https://doi.org/10.3390/nano12162826
    [37] Singh N, Manshian B, Jenkins GJ, et al. (2009) NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 30: 3891-3914. https://doi.org/10.1016/j.biomaterials.2009.04.009
    [38] Landsiedel R, Honarvar N, Seiffert SB, et al. (2022) Genotoxicity testing of nanomaterials. WIRES: Nanomed Nanobiotechnol 14: e1833. https://doi.org/10.1002/wnan.1833
    [39] Møller P, Roursgaard M (2024) Gastrointestinal tract exposure to particles and DNA damage in animals: a review of studies before, during, and after the peak of nanotoxicology. Mut Res/Rev Mutat Res 793: 108491. https://doi.org/10.1016/j.mrrev.2024.108491
    [40] Chow JCL (2021) Synthesis and applications of functionalized nanoparticles in biomedicine and radiotherapy. Additive Manufacturing with Functionalized Nanomaterials.Elsevier 193-214. https://doi.org/10.1016/B978-0-12-823152-4.00001-6
    [41] Chompoosor A, Saha K, Ghosh PS, et al. (2010) The role of surface functionality on acute cytotoxicity, ROS generation and DNA damage by cationic gold nanoparticles. Small (Weinheim an der Bergstrasse, Germany) 6: 2246. https://doi.org/10.1002/smll.201000463
    [42] Carlson C, Hussain SM, Schrand AM, et al. (2008) Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 112: 13608-13619. https://doi.org/10.1021/jp712087m
    [43] Song MF, Li YS, Kasai H, et al. (2012) Metal nanoparticle-induced micronuclei and oxidative DNA damage in mice. J Clin Biochem Nutr 50: 211-216. https://doi.org/10.3164/jcbn.11-70
    [44] Sotiropoulos M, Henthorn NT, Warmenhoven JW, et al. (2017) Modelling direct DNA damage for gold nanoparticle enhanced proton therapy. Nanoscale 9: 18413-18422. https://doi.org/10.1039/C7NR07310K
    [45] Madannejad R, Shoaie N, Jahanpeyma F, et al. (2019) Toxicity of carbon-based nanomaterials: reviewing recent reports in medical and biological systems. Chem-Biol Interact 307: 206-222. https://doi.org/10.1016/j.cbi.2019.04.036
    [46] Heredia DA, Durantini AM, Durantini JE, et al. (2022) Fullerene C60 derivatives as antimicrobial photodynamic agents. J Photochem Photobiol Photochem Rev 51: 100471. https://doi.org/10.1016/j.jphotochemrev.2021.100471
    [47] Migliore L, Saracino D, Bonelli A, et al. (2010) Carbon nanotubes induce oxidative DNA damage in RAW 264.7 cells. Environ Mol Mutagen 51: 294-303. https://doi.org/10.1002/em.20545
    [48] Oh WK, Kwon OS, Jang J (2013) Conducting polymer nanomaterials for biomedical applications: cellular interfacing and biosensing. Polym Rev 53: 407-442. https://doi.org/10.1080/15583724.2013.805771
    [49] Kulkarni AA, Rao PS (2013) Synthesis of polymeric nanomaterials for biomedical applications. Nanomaterials in Tissue Engineering.Woodhead Publishing 27-63. https://doi.org/10.1533/9780857097231.1.27
    [50] Li J, Pu K (2020) Semiconducting polymer nanomaterials as near-infrared photoactivatable protherapeutics for cancer. Acc Chem Res 53: 752-762. https://doi.org/10.1021/acs.accounts.9b00569
    [51] Balasubramanian SB, Gurumurthy B, Balasubramanian A (2017) Biomedical applications of ceramic nanomaterials: a review. Int J Pharm Sci Res 8: 4950-4959. https://doi.org/10.13040/IJPSR.0975-8232.8(12).4950-59
    [52] Jafari S, Mahyad B, Hashemzadeh H, et al. (2020) Biomedical applications of TiO2 nanostructures: recent advances. Int J Nanomed 15: 3447-3470. https://doi.org/10.2147/IJN.S249441
    [53] Huang Y, Li P, Zhao R, et al. (2022) Silica nanoparticles: biomedical applications and toxicity. Biomed Pharmacother 151: 113053. https://doi.org/10.1016/j.biopha.2022.113053
    [54] Chen L, Liu J, Zhang Y, et al. (2018) The toxicity of silica nanoparticles to the immune system. Nanomedicine 13: 1939-1962. https://doi.org/10.2217/nnm-2018-0076
    [55] Dolai J, Mandal K, Jana NR (2021) Nanoparticle size effects in biomedical applications. ACS Appl Nano Mater 4: 6471-6496. https://doi.org/10.1021/acsanm.1c00987
    [56] Albanese A, Tang PS, Chan WC (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14: 1-6. https://doi.org/10.1146/annurev-bioeng-071811-150124
    [57] Yang H, Liu C, Yang D, et al. (2009) Comparative study of cytotoxicity, oxidative stress, and genotoxicity induced by four typical nanomaterials: the role of particle size, shape, and composition. J Appl Toxicol 29: 69-78. https://doi.org/10.1002/jat.1385
    [58] Khaing Oo MK, Yang Y, Hu Y, et al. (2012) Gold nanoparticle-enhanced and size-dependent generation of reactive oxygen species from protoporphyrin IX. ACS Nano 6: 1939-1947. https://doi.org/10.1021/nn300327c
    [59] Kang Z, Yan X, Zhao L, et al. (2015) Gold nanoparticle/ZnO nanorod hybrids for enhanced reactive oxygen species generation and photodynamic therapy. Nano Res 8: 2004-2014. https://doi.org/10.1007/s12274-015-0712-3
    [60] Subbiah R, Veerapandian M, Yun KS (2010) Nanoparticles: Functionalization and multifunctional applications in biomedical sciences. Curr Med Chem 17: 4559-4577. https://doi.org/10.2174/092986710794183024
    [61] Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 7: 5577-5591. https://doi.org/10.2147/IJN.S36111
    [62] Siddique S, Chow JCL (2020) Gold nanoparticles for drug delivery and cancer therapy. Appl Sci 10: 3824. https://doi.org/10.3390/app10113824
    [63] Suk JS, Xu Q, Kim N, et al. (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99: 28-51. https://doi.org/10.1016/j.addr.2015.09.012
    [64] Shi M, Kwon HS, Peng Z, et al. (2012) Effects of surface chemistry on the generation of reactive oxygen species by copper nanoparticles. ACS Nano 6: 2157-2164. https://doi.org/10.1021/nn300445d
    [65] Čapek J, Roušar T (2021) Detection of oxidative stress induced by nanomaterials in cells—the roles of reactive oxygen species and glutathione. Molecules 26: 4710. https://doi.org/10.3390/molecules26164710
    [66] Magdolenova Z, Bilaničová D, Pojana G, et al. (2012) Impact of agglomeration and different dispersions of titanium dioxide nanoparticles on the human related in vitro cytotoxicity and genotoxicity. J Environ Monitor 14: 455-464. https://doi.org/10.1039/C2EM10746E
    [67] Behzadi S, Serpooshan V, Tao W, et al. (2017) Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 46: 4218-4244. https://doi.org/10.1039/C6CS00636A
    [68] Soto K, Garza KM, Murr LE (2007) Cytotoxic effects of aggregated nanomaterials. Acta Biomater 3: 351-358. https://doi.org/10.1016/j.actbio.2006.11.004
    [69] Liu Y, Zhu S, Gu Z, et al. (2022) Toxicity of manufactured nanomaterials. Particuology 69: 31-48. https://doi.org/10.1016/j.partic.2021.11.007
    [70] Walkey CD, Chan WC (2012) Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 41: 2780-2799. https://doi.org/10.1039/C1CS15233E
    [71] Lee YK, Choi EJ, Webster TJ, et al. (2015) Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomed 10: 97-113. https://doi.org/10.2147/IJN.S72998
    [72] Bushell M, Beauchemin S, Kunc F, et al. (2020) Characterization of commercial metal oxide nanomaterials: Crystalline phase, particle size, and specific surface area. Nanomaterials 10: 1812. https://doi.org/10.3390/nano10091812
    [73] Mahaye N, Thwala M, Cowan DA, et al. (2017) Genotoxicity of metal-based engineered nanoparticles in aquatic organisms: a review. Mut Res/Rev Mut Res 773: 134-160. https://doi.org/10.1016/j.mrrev.2017.05.004
    [74] Zijno A, De Angelis I, De Berardis B, et al. (2015) Different mechanisms are involved in oxidative DNA damage and genotoxicity induction by ZnO and TiO2 nanoparticles in human colon carcinoma cells. Toxicol Vitro 29: 1503-1512. https://doi.org/10.1016/j.tiv.2015.06.009
    [75] Racovita AD (2022) Titanium dioxide: structure, impact, and toxicity. Int J Environ Res Public Health 19: 5681. https://doi.org/10.3390/ijerph19095681
    [76] Sukhanova A, Bozrova S, Sokolov P, et al. (2018) Dependence of nanoparticle toxicity on their physical and chemical properties. Nanoscale Res Lett 13: 44. https://doi.org/10.1186/s11671-018-2457-x
    [77] Thu HE, Haider MA, Khan S, et al. (2023) Nanotoxicity induced by nanomaterials: a review of factors affecting nanotoxicity and possible adaptations. OpenNano 14: 100190. https://doi.org/10.1016/j.onano.2023.100190
    [78] Sirajuddin M, Ali S, Badshah A (2013) Drug–DNA interactions and their study by UV–Visible, fluorescence spectroscopies, and cyclic voltammetry. J Photoch Photobio B 124: 1-9. https://doi.org/10.1016/j.jphotobiol.2013.03.013
    [79] Wamsley M, Zou S, Zhang D (2023) Advancing evidence-based data interpretation in UV–Vis and fluorescence analysis for nanomaterials: an analytical chemistry perspective. Anal Chem 95: 17426-17437. https://doi.org/10.1021/acs.analchem.3c03490
    [80] Suh JS, Kim TJ (2023) A novel DNA double-strand breaks biosensor based on fluorescence resonance energy transfer. Biomater Res 27: 15. https://doi.org/10.1186/s40824-023-00354-1
    [81] Kolyvanova MA, Klimovich MA, Belousov AV, et al. (2022) A principal approach to the detection of radiation-induced DNA damage by circular dichroism spectroscopy and its dosimetric application. Photonics 9: 787. https://doi.org/10.3390/photonics9110787
    [82] Xu X, Nakano T, Tsuda M, et al. (2020) Direct observation of damage clustering in irradiated DNA with atomic force microscopy. Nucleic Acids Res 48: e18. https://doi.org/10.1093/nar/gkz1159
    [83] Rübe CE, Lorat Y, Schuler N, et al. (2011) DNA repair in the context of chromatin: new molecular insights by the nanoscale detection of DNA repair complexes using transmission electron microscopy. DNA Repair 10: 427-437. https://doi.org/10.1016/j.dnarep.2011.01.012
    [84] Scalisi S, Privitera AP, Pelicci PG, et al. (2024) Origin and evolution of oncogene-related DNA damage: a confocal imaging study. Biophys J 123: 290a-291a. https://doi.org/10.1016/j.bpj.2023.11.1811
    [85] Darwanto A, Farrel A, Rogstad DK, et al. (2009) Characterization of DNA glycosylase activity by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem 394: 13-23. https://doi.org/10.1016/j.ab.2009.07.015
    [86] Chaudhary AK, Nokubo M, Oglesby TD, et al. (1995) Characterization of endogenous DNA adducts by liquid chromatography/electrospray ionization tandem mass spectrometry. J Mass Spectrom 30: 1157-1166. https://doi.org/10.1002/jms.1190300813
    [87] Kaneko S, Takamatsu K (2024) Angle modulated two-dimensional single cell pulsed-field gel electrophoresis for detecting early symptoms of DNA fragmentation in human sperm nuclei. Sci Rep 14: 840. https://doi.org/10.1038/s41598-024-51509-6
    [88] Plitta-Michalak BP, Ramos A, Stępień D, et al. (2024) Pespective: the comet assay as a method for assessing DNA damage in cryopreserved samples. CryoLetters 45: 1-5. https://doi.org/10.54680/fr24110110112
    [89] Chatha AMM, Naz S, Iqbal SS, et al. (2024) Detection of DNA damage in fish using comet assay. Curr Trends in OMICS 4: 01-16. https://doi.org/10.32350/cto.41.01
    [90] Li H, Xu Y, Shi W, et al. (2017) Assessment of alterations in X-ray irradiation-induced DNA damage of glioma cells by using proton nuclear magnetic resonance spectroscopy. Int J Biochem Cell Biol 84: 109-118. https://doi.org/10.1016/j.biocel.2017.01.010
    [91] Campagne S, Gervais V, Milon A (2011) Nuclear magnetic resonance analysis of protein–DNA interactions. J R Soc Interface 8: 1065-1078. https://doi.org/10.1098/rsif.2010.0543
    [92] Abolfath RM, Carlson DJ, Chen ZJ, et al. (2013) A molecular dynamics simulation of DNA damage induction by ionizing radiation. Phys Med Biol 58: 7143. https://doi.org/10.1088/0031-9155/58/20/7143
    [93] Yang S, Zhao T, Zou L, et al. (2019) ReaxFF-based molecular dynamics simulation of DNA molecules destruction in cancer cells by plasma ROS. Phys Plasmas 26: 083504. https://doi.org/10.1063/1.5097243
    [94] Sheeraz Z, Chow JCL (2021) Evaluation of dose enhancement with gold nanoparticles in kilovoltage radiotherapy using the new EGS geometry library in Monte Carlo simulation. AIMS Biophys 8: 337-345. https://doi.org/10.3934/biophy.2021027
    [95] Leung MK, Chow JC, Chithrani BD, et al. (2011) Irradiation of gold nanoparticles by x-rays: Monte Carlo simulation of dose enhancements and the spatial properties of the secondary electrons production. Med Phys 38: 624-631. https://doi.org/10.1118/1.3539623
    [96] Chow JCL (2018) Monte Carlo nanodosimetry in gold nanoparticle-enhanced radiotherapy. Recent Advancements and Applications in Dosimetry. New York: Nova Science Publishers.
    [97] Jabeen M, Chow JCL (2021) Gold nanoparticle DNA damage by photon beam in a magnetic field: a Monte Carlo study. Nanomaterials 11: 1751. https://doi.org/10.3390/nano11071751
    [98] Chun H, Chow JCL (2016) Gold nanoparticle DNA damage in radiotherapy: a Monte Carlo study. AIMS Bioeng 3: 352-361. https://doi.org/10.3934/bioeng.2016.3.352
    [99] Horvath T, Papp A, Igaz N, et al. (2018) Pulmonary impact of titanium dioxide nanorods: examination of nanorod-exposed rat lungs and human alveolar cells. Int J Nanomed 13: 7061-7077. https://doi.org/10.2147/IJN.S179159
    [100] AshaRani PV, Low Kah Mun G, Hande MP, et al. (2009) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3: 279-290. https://doi.org/10.1021/nn800596w
    [101] Karlsson HL, Cronholm P, Gustafsson J, et al. (2008) Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res Toxicol 21: 1726-1732. https://doi.org/10.1021/tx800064j
    [102] Singh N, Manshian B, Jenkins GJ, et al. (2009) NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 30: 3891-3914. https://doi.org/10.1016/j.biomaterials.2009.04.009
    [103] Magdolenova Z, Collins A, Kumar A, et al. (2014) Mechanisms of genotoxicity: a review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology 8: 233-278. https://doi.org/10.3109/17435390.2013.773464
    [104] Gonzalez L, Lison D, Kirsch-Volders M (2008) Genotoxicity of engineered nanomaterials: a critical review. Nanotoxicology 2: 252-273. https://doi.org/10.1080/17435390802464986
    [105] Ahamed M, Karns M, Goodson M, et al. (2008) DNA damage response to different surface chemistry of silver nanoparticles in mammalian cells. Toxicol Appl Pharm 233: 404-410. https://doi.org/10.1016/j.taap.2008.09.015
    [106] Shukla RK, Sharma V, Pandey AK, et al. (2011) ROS-mediated genotoxicity induced by titanium dioxide nanoparticles in human epidermal cells. Toxicol in Vitro 25: 231-241. https://doi.org/10.1016/j.tiv.2010.11.008
    [107] Sharma V, Singh P, Pandey AK, et al. (2012) Induction of oxidative stress and DNA damage by zinc oxide nanoparticles in human liver cells (HepG2). J Biomed Nanotechnol 8: 63-65. https://doi.org/10.1016/j.mrgentox.2011.12.009
    [108] Oberdörster G, Oberdörster E, Oberdörster J (2005) Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Persp 113: 823-839. https://doi.org/10.1289/ehp.7339
    [109] Park EJ, Yi J, Kim Y, et al. (2010) Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol Vitro 24: 872-878. https://doi.org/10.1016/j.tiv.2009.12.001
    [110] Chen Z, Meng H, Xing G, et al. (2006) Acute toxicological effects of copper nanoparticles in vivo. Toxicol Lett 163: 109-120. https://doi.org/10.1016/j.toxlet.2005.10.003
    [111] Trouiller B, Reliene R, Westbrook A, et al. (2009) Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice. Cancer Res 69: 8784-8789. https://doi.org/10.1158/0008-5472.CAN-09-2496
    [112] Folkmann JK, Risom L, Jacobsen NR, et al. (2009) Oxidatively damaged DNA in rats exposed by oral gavage to C60 fullerenes and single-walled carbon nanotubes. Environ Health Persp 117: 703-708. https://doi.org/10.1289/ehp.11922
    [113] Bahamonde J, Brenseke B, Prater MR, et al. (2018) Gold nanoparticles toxicity in mice and rats: species differences. Toxicol Pathol 46: 431-443. https://doi.org/10.1177/0192623318770608
    [114] Lam CW, James JT, McCluskey R, et al. (2004) Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 77: 26-134. https://doi.org/10.1093/toxsci/kfg243
    [115] Pan Y, Neuss S, Leifert A, et al. (2007) Size-dependent cytotoxicity of gold nanoparticles. Small 3: 1941-1949. https://doi.org/10.1002/smll.200700378
    [116] Jiang W, Kim BY, Rutka JT, et al. (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3: 145-150. https://doi.org/10.1038/nnano.2008.30
    [117] Zhang XD, Wu D, Shen X, et al. (2012) Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomed 6: 2071-2081. https://doi.org/10.2147/IJN.S21657
    [118] Derfus AM, Chan WC, Bhatia SN (2004) Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 4: 11-18. https://doi.org/10.1021/nl0347334
    [119] Ahamed M, Siddiqui MK, Akhtar MJ, et al. (2010) Genotoxic potential of copper oxide nanoparticles in human lung epithelial cells. Biochem Bioph Res Co 396: 578-583. https://doi.org/10.1016/j.bbrc.2010.04.156
    [120] Kang S, Pinault M, Pfefferle LD, et al. (2008) Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langmuir 24: 6409-6413. https://doi.org/10.1021/la701067r
    [121] Limbach LK, Wick P, Manser P, et al. (2007) Exposure of engineered nanoparticles to human lung epithelial cells: Influence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol 41: 4158-4163. https://doi.org/10.1021/es062629t
    [122] Collins AR (2004) The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26: 249-261. https://doi.org/10.1385/MB:26:3:249
    [123] Fenech M (2000) The in vitro micronucleus technique. Mutat Res/Fund Mol M 455: 81-95. https://doi.org/10.1016/S0027-5107(00)00065-8
    [124] Rogakou EP, Pilch DR, Orr AH, et al. (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868. https://doi.org/10.1074/jbc.273.10.5858
    [125] Olive PL, Banáth JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23-29. https://doi.org/10.1038/nprot.2006.5
    [126] Kirsch-Volders M, Sofuni T, Aardema M, et al. (2011) Report from the in vitro micronucleus assay working group. Mut Res/Genet Toxicol Environ Mutagen 540: 153-163. https://doi.org/10.1016/j.mrgentox.2003.07.005
    [127] Mah LJ, El-Osta A, Karagiannis TC (2010) γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24: 679-686. https://doi.org/10.1038/leu.2010.6
    [128] AshaRani PV, Low Kah Mun G, Hande MP, et al. (2009) Cytotoxicity and genotoxicity of silver nanoparticles. ACS Nano 3: 279-290. https://doi.org/10.1021/nn800596w
    [129] Gurr JR, Wang AS, Chen CH, et al. (2005) Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology 213: 66-73. https://doi.org/10.1016/j.tox.2005.05.007
    [130] Migliore L, Saracino S, Bonfiglioli R, et al. (2010) Carbon nanotubes induce oxidative DNA damage in RAW264.7 cells. Environ Mol Mutagen 51: 294-303. https://doi.org/10.1002/em.20545
    [131] Tsuchiya T, Oguri I, Yamakoshi YN, et al. (1996) Novel harmful effects of [60] fullerene on mouse embryos in vitro and in vivo. EBS Lett 393: 139-145. https://doi.org/10.1016/0014-5793(96)00812-5
    [132] Gupta SK, Sundarraj K, Devashya N, et al. (2013) ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53-p21 mediated ROS generation and mitochondrial oxidative stress. Biotechnol Bioeng 110: 3113-3122. https://doi.org/10.1016/j.tiv.2011.08.011
    [133] Chow JCL (2018) Recent progress in Monte Carlo simulation on gold nanoparticle radiosensitization. AIMS Biophys 5: 231-244. https://doi.org/10.3934/biophy.2018.4.231
    [134] Chithrani DB, Jelveh S, Jalali F, et al. (2010) Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res 173: 719-728. https://doi.org/10.1667/RR1984.1
    [135] Zheng XJ, Chow JCL (2017) Radiation dose enhancement in skin therapy with nanoparticle addition: a Monte Carlo study on kilovoltage photon and megavoltage electron beams. World J Radiol 9: 63-71. https://doi.org/10.4329/wjr.v9.i2.63
    [136] Chow JCL (2020) Depth dose enhancement on flattening-filter-free photon beam: a Monte Carlo study in nanoparticle-enhanced radiotherapy. Appl Sci 10: 7052. https://doi.org/10.3390/app10207052
    [137] Cho SH, Jones BL, Krishnan S (2005) The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/X-ray sources. Phys Med Biol 50: N163-N173. https://doi.org/10.1088/0031-9155/54/16/004
    [138] Cho S, Jeong JH, Kim CH, et al. (2010) Monte Carlo simulation study on dose enhancement by gold nanoparticles in brachytherapy. J Korean Phys Soc 56: 1754-1758. https://doi.org/10.3938/jkps.56.1754
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1034) PDF downloads(58) Cited by(7)

Figures and Tables

Figures(4)  /  Tables(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog